Results 121 to 130 of about 64,621 (307)

Studies on the behaviour of human pancreatic carcinoma cell lines, with particular reference to stem cells

, 2010
PhDStem cell therapy represents a potential -cell replacement strategy in diabetes and a pancreatic cancer (PC) stem cell is an attractive therapeutic target in this dire disease. However, a normal stem cell remains unidentified and proposed malignant
Guppy, Naomi J
core  

Mast cells and angiogenesis in pancreatic ductal adenocarcinoma

, 2018
Mast cells are recognized as critical components of the tumor stromal microenvironment in several solid and hematological malignancies, promoting angiogenesis and tumor growth.
Roberto Tamma, Pisconti, Salvatore, Silvestris, Nicola, Domenico Ribatti, Longo, Vito, Tamma, Roberto, Oronzo Brunetti, Antonella Argentiero, Argentiero, Antonella, Nicola Silvestris, Salvatore Pisconti, Ribatti, Domenico, Vito Longo, Brunetti, Oronzo   +13 more
core   +1 more source

A dose‐finding population pharmacokinetic/pharmacodynamic model of ginisortamab, an anti‐gremlin‐1 monoclonal antibody, in patients with solid tumours

British Journal of Clinical Pharmacology, EarlyView.
Aims Ginisortamab, a first‐in‐class human monoclonal antibody for the treatment of advanced solid tumours, binds to gremlin‐1 and restores bone morphogenetic protein signalling. We used pharmacokinetic/pharmacodynamic (PK/PD) modelling to characterize the relationship between ginisortamab dose and serum gremlin‐1 binding, using model‐based simulations ...
Yin Cheong Wong, Luisa Rojas Chavarro, Paul Jones, David Egging, Wanchana Ungphakorn, Marta Valle, Ivan Matthews   +6 more
wiley   +1 more source

Identification of epidermal Pdx1 expression discloses different roles of Notch1 and Notch2 in murine KrasG12D-induced skin carcinogenesis in vivo [PDF]

, 2010
Background The Ras and Notch signaling pathways are frequently activated during development to control many diverse cellular processes and are often dysregulated during tumorigenesis.
Mazur Pawel K., Radtke, Freddy, Freddy Radtke, Roland M Schmid, Schmid, Roland M., Nakhai Hassan, Grüner, Barbara M., Pawel K Mazur, Schmid Roland M., Barbara M. Grüner, Bence Sipos, Nakhai, Hassan, Jens T Siveke, Strobl Lothar J., Siveke, J.T., Mazur, P.K., Radtke Freddy, Sipos, Bence, Radtke, F., Barbara M Grüner, Zimber-Strobl Ursula, Nakhai, H., Jens T. Siveke, Sipos, B., Grüner, B.M., Schmid, R.M., Strobl, Lothar J., Grüner Barbara M., Strobl, L.J., Lothar J Strobl, Lothar J. Strobl, Zimber-Strobl, Ursula, Hassan Nakhai, Pawel K. Mazur, Roland M. Schmid, Mazur, Pawel K., Ursula Zimber-Strobl, Sipos Bence, Siveke Jens T., Zimber-Strobl, U., Siveke, Jens T.   +40 more
core   +1 more source

Cold atmospheric plasma‐mediated tumor microenvironment remodeling for cancer treatment

BMEMat, EarlyView.
Schematic presentation of CAP‐mediated TME remodeling. This review summarizes recent efforts in cold atmospheric plasma (CAP) application in cancer treatment, highlighting the anticancer potential of CAP, molecular mechanisms, and future perspectives for further improvement and clinical translation.
Israr Khan, Qiujie Fang, Cao Fei, Ziyuan Wang, Zhaowei Chen, Guojun Chen, Zhiming Xu, Shu Xu, Zhitong Chen   +8 more
wiley   +1 more source

Characterization of the neuroendocrine pancreatic tumors nature by MDCT enhancement pattern: a radio-pathological correlation

, 2012
Introduction Pre-operative suspicion of neuroendocrine pancreatic lesions nature arises both from clinical (presence and the type of secreted hormone) and imaging findings.
NOVARIA, LISA
core  

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

BMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao, Rui Qu, Zan Dai, Xiqun Jiang, Xu Zhen   +4 more
wiley   +1 more source

Expression studies on PPARγ in pancreatic neuroendocrine tumours

, 2010
MDPancreatic NETs occur with an annual incidence of around 5 per 1,000,000 population per year, with survival rates of between 30 – 97% at 5 years depending on the tumour subtype.
Hanson, Matthew Richard
core  

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source